We Update you with the Clock Running. Health Care News, Disease, Diagnose, Physicians, Residents, Medical Officers, Nursing Care, Technical Staff, Health Policies, Organizations, Certification, Standards, Alerts, and All about Worlds Health. Step to Facilitate the Health Care Professionals and Patients. Provide Safety and Quality to Patient's, Health Care staff, Explains Patient Family Education and Rights.
Top-Line Efficacy Data Presented From Phase 2 Trial Of Alemtuzumab In Multiple Sclerosis
Multiple Sclerosis Genzyme Corporation (Nasdaq: GENZ) announced that top-line, three-year data from a completed Phase 2 clinical trial comparing alemtuzumab with Rebif(R) (interferon beta- 1a) for the treatment of multiple sclerosis were presented this weekend at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague. The results come from an analysis conducted after 36 months of treatment for 334 patients in the three-year trial. [click link for full article]
Custom Search
